***Background.*** The broth microdilution (BMD) method for telavancin (TLV) was recently revised by the FDA and CLSI. This study assessed the TLV activity using a revised BMD (rBMD) method, following the CLSI guidelines for water-insoluble agents. Polysorbate-80 was added in the test medium. This rBMD method was deemed necessary for greater accuracy and reproducibility of TLV MIC results.

***Methods.*** 9,610 *S. aureus*collected from 28 USA sites were included. Susceptibility testing was performed based on CLSI guidelines (M07-A9 and M100-S24). MIC interpretation was guided by FDA (TLV) and CLSI (2014) criteria. MRSA resistant to ≥3 drug classes were defined as MDR.

***Results.*** TLV had MIC~50~, MIC~90~ and MIC~100~ of 0.03, 0.06 and 0.12 µg/mL, respectively, against methicillin-susceptible, MRSA, non-MDR and MDR subsets. MRSA with vancomycin (VAN) MIC = 2 µg/mL had TLV MIC~50~ (0.06 µg/mL) 2-fold higher than those MRSA with VAN MIC at ≤1 µg/mL. These TLV MIC~50~ results were equivalent to those noted for MRSA categorized by the daptomycin (DAP) MICs. However, TLV had MIC~90~ and MIC~100~ results of 0.06 and 0.12 µg/mL, respectively, regardless of MRSA subset. VAN (MIC~50/90~, 1/1 µg/mL), DAP (MIC~50/90~, 0.25/0.5 µg/mL) and linezolid (MIC~50/90~, 1/1 µg/mL) were active against MDR (≥99.7% susceptible); however, TLV had MICs 8- to 32-fold lower than these comparators.

  *S. aureus* (no. tested)   MIC (µg/mL)   Number (cumulative %) inhibited at MIC (µg/mL)                                           
  -------------------------- ------------- ------------------------------------------------ ----------- ------------- ------------- ------------
  All (9,610)                0.03          0.06                                             364 (3.8)   6210 (68.4)   3012 (99.8)   24 (100.0)
  MSSA (4,959)               0.03          0.03                                             242 (4.9)   3272 (70.9)   1437 (99.8)   8 (100.0)
  MRSA (4,651)               0.03          0.06                                             122 (2.6)   2938 (65.8)   1575 (99.7)   16 (100.0)
  VAN ≤1 µg/mL (4,561)       0.03          0.06                                             119 (2.6)   2930 (66.8)   1502 (99.8)   10 (100.0)
  VAN = 2 µg/mL (90)         0.06          0.06                                             3 (3.3)     8 (12.2)      73 (93.3)     6 (100.0)
  DAP ≤0.5 µg/mL (4,607)     0.03          0.06                                             122 (2.6)   2928 (66.2)   1545 (99.7)   12 (100.0)
  DAP = 1-2 µg/mL (43)       0.06          0.06                                             0 (0.0)     9 (20.9)      30 (90.7)     4 (100.0)
  MDR (1,371)                0.03          0.06                                             37 (2.7)    749 (57.3)    574 (99.2)    11 (100.0)
  Non-MDR (3,280)            0.03          0.06                                             85 (2.6)    2189 (69.3)   1001 (99.8)   5 (100.0)

***Conclusion.*** TLV had potent activity against *S. aureus*, including less susceptible and MDR subsets, inhibiting all *S*. *aureus* at ≤0.12 µg/mL, the FDA breakpoint for susceptibility. These results establish the new benchmark for TLV activity.
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